News
Read the latest from M8.
Apr 02, 2024
Acino announces new regional Leadership and hub to deliver on expanded presence and capabilities in LATAM following M8 acquisition Joel Barlan appointed as head of LATAM region
Mar 19, 2024
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
Dec 04, 2023
Acino Completes Acquisition of M8 Pharmaceuticals Significantly Expanding Presence and Capabilities In Latin America
Sep 20, 2023
Acino Significantly Expands Presence and Capabilities in Latin America Through Acquisition of M8 Pharmaceuticals
Aug 01, 2023
M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
moksha8 Pharmaceuticals and CHEPLAPHARM enter into a strategic partnership to distribute Questran® in Mexico and Brazil
Oct 31, 2018
moksha8 Pharmaceuticals and the German pharmaceutical company CHEPLAPHARM Arzneimittel GmbH have signed an agreement on the basis of which moksha8 will commercialize and promote Questran® in Mexico and Brazil.
Questran® (Cholestyramine) is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein [LDL] cholesterol).
High level of cholesterol increases the risks of heart disease and stroke. Globally, a third of ischaemic heart disease is attributable to high cholesterol. Overall, hypercholesterolemia is estimated to cause 2.6 million deaths. Prevalence for high cholesterol among adults is 39% worldwide (37% for males and 40% for females) - the highest prevalence according to WHO is found in Europe (54% for both sexes), followed by the Americas (48% for both sexes).
In Latin America, lipid abnormalities have a high prevalence and this is related to multiple causes: Genetic load and epigenetic modifications combined with a sedentary lifestyle and an inadequate nutrition*.
Questran® (Cholestyramine) has proven efficacy, if used along with a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks.
Since last year, with the distribution agreement for Dilatrend® in Mexico, moksha8 and CHEPLAPHARM have established a great partnership and, due to the positive results achieved, the companies decided to expand their commercial relationship in the Latin American country.
With this agreement, moksha8 Pharmaceuticals continues with its global diversification strategy and is increasing its cardiology portfolio. In Mexico, Questran® is the second product in the cardiology line and in the case of Brazil, Questran® will be the therapy with which the subsidiary will enter into this therapeutic area.
moksha8 is committed to work hard to maximize the product value of Questran® and to further contribute to hypercholesterolemia treatments in the Latin American region.
** World Health Organization/cholesterol, 2011**